Figure 1 | Gene Therapy

Figure 1

From: Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy

Figure 1

Reovirus primes a Th1 response, while VSV-cDNA primes a Th17 response against B16 melanoma. (a, b) C57Bl/6 mice (4 per group) bearing 10-day established B16 tumours, received six i.t. injections of either PBS or Reovirus on days 10, 12, 14, 17, 19, 21 (a), and C57Bl/6 mice (4 per group) bearing 5-day established B16 tumours, received six i.v. injections of either VSV-GFP or VSV-ASMEL on days 5, 7, 9, 12, 14, 16. (b). At day 25, mice were euthanised, spleens and LN dissociated into single cell suspensions and re-stimulated with either: B16 F/T lysate; VSV-NRAS+VSV-CYT-c+VSV-TYRP1 (VSV-combo, total MOI=1 per re-stimulation) or peptide as indicated (1 μg/ml per re-stimulation) every 24 h. Supernatants were harvested after 48 h and tested for IFN-γ and IL-17 by ELISA. Graphs show values +s.d. (triplicate wells) for individual mice. *P<0.05, **P<0.01 two-tailed t-test.

Back to article page